LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Effect of Exercise on β-Endorphin and Its Receptors in Myasthenia Gravis Patients.

    Tripathi, Gyanesh M / Misra, Usha K / Kalita, Jayantee / Singh, Varun K / Tripathi, Abhilasha

    Molecular neurobiology

    2023  Volume 60, Issue 6, Page(s) 3010–3019

    Abstract: This is a prospective observational study evaluating the change in β-endorphin (BE) and its receptors following exercise in patients with myasthenia gravis (MG) and their association with clinical improvement. Fifteen patients with mild to moderate MG, ... ...

    Abstract This is a prospective observational study evaluating the change in β-endorphin (BE) and its receptors following exercise in patients with myasthenia gravis (MG) and their association with clinical improvement. Fifteen patients with mild to moderate MG, aged 16-70 years, who were able to do 6-Minute Walk Test (6-MWT) and had MG Quality of Life-15 (MGQoL-15) ≤ 45 without any contraindication for exercise were included. The patients walked 30 min daily for 3 months. The primary outcome at 3 months was > 50% improvement in MGQoL-15 from the baseline, and the secondary outcomes were MG Activities of Daily Living (MGADL), Hospital Anxiety and Depression Scale (HADS), number of steps, and distance covered on 6-MWT and adverse events. Plasma BE level, μ-opioid receptor (MOR), and δ-opioid receptor (DOR) were measured on admission and at 1 and 3 months. Twelve age- and gender-matched healthy controls who were not on regular exercise were included for comparison of BE, MOR, and DOR levels. Plasma BE level (P = 0.007) and DOR expression (P = 0.001) were lower in MG patients compared to the healthy controls. After 3 months of exercise, 6 patients improved. Plasma BE, MOR, and DOR levels increased in the first and decreased in the third month. MGQoL-15 (P < 0.001), HADS (P < 0.0001), number of steps (P < 0.007), distance (P = 0.030), and MGADL (P < 0.001) significantly improved compared to baseline. At 3 months, MGQoL-15 was associated with HADS score (P = 0.001), reduced depression (P = 0.013), MGADL (P = 0.035), and distance travelled on the 6-WMW test (P = 0.050). The improvement in depression was associated with higher BE level.
    MeSH term(s) Humans ; beta-Endorphin ; Quality of Life ; Activities of Daily Living ; Receptors, Opioid, mu/metabolism ; Myasthenia Gravis ; Exercise
    Chemical Substances beta-Endorphin (60617-12-1) ; Receptors, Opioid, mu
    Language English
    Publishing date 2023-02-13
    Publishing country United States
    Document type Observational Study ; Journal Article
    ZDB-ID 645020-9
    ISSN 1559-1182 ; 0893-7648
    ISSN (online) 1559-1182
    ISSN 0893-7648
    DOI 10.1007/s12035-023-03247-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Role of glutamate and its receptors in migraine with reference to amitriptyline and transcranial magnetic stimulation therapy.

    Tripathi, Gyanesh M / Kalita, Jayantee / Misra, Usha K

    Brain research

    2018  Volume 1696, Page(s) 31–37

    Abstract: Glutamate plays an important role in migraine pathogenesis but there is paucity of studies on glutamate in migraine subtypes, effect of treatment on glutamate levels and the changes in glutamate receptors. In this study we report the glutamate levels and ...

    Abstract Glutamate plays an important role in migraine pathogenesis but there is paucity of studies on glutamate in migraine subtypes, effect of treatment on glutamate levels and the changes in glutamate receptors. In this study we report the glutamate levels and changes in glutamate receptors following amitriptyline (AMT) or repetitive Transcranial Magnetic Stimulation (rTMS) therapy. One hundred and fifty migraine patients having more than 4 migraine attacks per month were included. Thirty patients were treated with AMT and 120 with rTMS; 24 patients received 3 sessions, 36 received single session of rTMS and 60 patients received sham stimulation. The severity of headache was assessed by VAS score, Migraine Index (MI) and frequency of headache. Good outcome was defined by 50% improvement in headache frequency; severity and MI. Plasma glutamate level were measured by enzyme linked immunosorbant assay and relative expression of NR2B and mGluR3 receptors by real time polymerase chain reaction. The changes in these parameters before and after treatment were measured and correlated with the clinical parameters. Glutamate levels (P = 0.006) and NR2B receptor expressions (P < 0.001) were significantly higher in migraine patients compared to the controls. Chronic migraine patients had higher glutamate level (P = 0.05). Glutamate and NR2B receptor declined after treatment (P < 0.001). There was a decline in glutamate levels following rTMS (P = 0.03), sham stimulation (P = 0.05) and AMT treatment (P = 0.003). NR2B receptors also declined after rTMS (P = 0.005) and AMT treatment (P = 0.01). It can be concluded that migraine is associated with high plasma glutamate and NR2B receptor which decline following AMT or rTMS therapy.
    MeSH term(s) Adolescent ; Adult ; Amitriptyline/pharmacology ; Female ; Glutamic Acid/analysis ; Glutamic Acid/metabolism ; Glutamic Acid/physiology ; Humans ; Male ; Middle Aged ; Migraine Disorders/physiopathology ; Migraine Disorders/therapy ; Receptors, Glutamate/analysis ; Receptors, Glutamate/metabolism ; Receptors, Glutamate/physiology ; Transcranial Magnetic Stimulation/methods
    Chemical Substances Receptors, Glutamate ; Amitriptyline (1806D8D52K) ; Glutamic Acid (3KX376GY7L)
    Language English
    Publishing date 2018-05-31
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1200-2
    ISSN 1872-6240 ; 0006-8993
    ISSN (online) 1872-6240
    ISSN 0006-8993
    DOI 10.1016/j.brainres.2018.05.046
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A study of oxidative stress in migraine with special reference to prophylactic therapy.

    Tripathi, Gyanesh M / Kalita, Jayantee / Misra, Usha K

    The International journal of neuroscience

    2018  Volume 128, Issue 4, Page(s) 318–324

    Abstract: Objective: The role of oxidative stress markers in migraine and effect of treatment on these has been reported.: Subjects and methods: One hundred and fifty patients having > four attacks of migraine headache/month were included. Headache severity, ... ...

    Abstract Objective: The role of oxidative stress markers in migraine and effect of treatment on these has been reported.
    Subjects and methods: One hundred and fifty patients having > four attacks of migraine headache/month were included. Headache severity, Migraine Index (MI) and frequency of headache were noted. 120 patients received repetitive transcranial magnetic stimulation (rTMS) therapy and 30 patients received Amitriptyline (AMT). Recovery was defined by 50% improvement in frequency, severity or reduction in MI. Oxidative stress and antioxidant markers have been estimated in patients before and after treatment and correlate the clinical and outcome parameters.
    Results: Glutathione (GSH) (P < 0.001), glutathione-S-transferase (GST) (P = 0.049) and total antioxidant activity (TAC) (P < 0.001) level were significantly reduced in migraine patients. GSH (P = 0.02), GST (P = 0.05) and TAC (P < 0.001) were reduced in ictal migraineurs compared to controls. GSH (P < 0.001) and TAC (P = 0.003) levels increased after treatment compared to the base line. There is an increase in GSH levels in the patients who had improved following rTMS (P = 0.003); placebo (P = 0.001) and AMT (P = 0.013). TAC levels were also increased following rTMS (P = 0.009) and AMT (P = 0.020).
    Conclusion: There is evidence of oxidative stress in migraine pathophysiology. Following treatment, oxidative stress declined following both pharmacological and rTMS.
    MeSH term(s) Adolescent ; Adult ; Aged ; Amitriptyline/therapeutic use ; Analgesics, Non-Narcotic/therapeutic use ; Antioxidants/metabolism ; Female ; Glutathione/metabolism ; Glutathione Transferase/metabolism ; Humans ; Male ; Malondialdehyde/metabolism ; Middle Aged ; Migraine Disorders/diagnostic imaging ; Migraine Disorders/physiopathology ; Migraine Disorders/therapy ; Oxidative Stress/drug effects ; Oxidative Stress/physiology ; ROC Curve ; Transcranial Magnetic Stimulation/methods ; Young Adult
    Chemical Substances Analgesics, Non-Narcotic ; Antioxidants ; Amitriptyline (1806D8D52K) ; Malondialdehyde (4Y8F71G49Q) ; Glutathione Transferase (EC 2.5.1.18) ; Glutathione (GAN16C9B8O)
    Language English
    Publishing date 2018-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 3061-2
    ISSN 1563-5279 ; 1543-5245 ; 0020-7454
    ISSN (online) 1563-5279 ; 1543-5245
    ISSN 0020-7454
    DOI 10.1080/00207454.2017.1374959
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Is β endorphin related to migraine headache and its relief?

    Misra, Usha K / Kalita, Jayantee / Tripathi, Gyanesh M / Bhoi, Sanjeev K

    Cephalalgia : an international journal of headache

    2013  Volume 33, Issue 5, Page(s) 316–322

    Abstract: Background: Low β endorphin level in serum and cerebrospinal fluid (CSF) has been reported in migraine. The basis of pain relief in migraine by repetitive transcranial magnetic stimulation (rTMS) may be related to β endorphin (BE), which has not been ... ...

    Abstract Background: Low β endorphin level in serum and cerebrospinal fluid (CSF) has been reported in migraine. The basis of pain relief in migraine by repetitive transcranial magnetic stimulation (rTMS) may be related to β endorphin (BE), which has not been evaluated. It is proposed to measure plasma β endorphin level in migraine patients and the change in β endorphin level following rTMS, and to correlate these changes with migraine relief.
    Methods: Twenty-five patients with migraine diagnosed as per International Headache Society criteria and 20 gender- and age-matched controls were included. Their clinical characteristics including duration of migraine, its frequency, severity and functional disability, triggers, allodynia and number of analgesic used were noted. Plasma β endorphin level was estimated before and after the third rTMS session. rTMS was delivered on the hot spot of right abductor digiti minimi on alternate days for 3 days and each session consisted of 600 pulses at 10 Hz. The clinical response was noted weekly for 1 month and correlated with β endorphin level.
    Results: The median age of the patients was 35 (20-50) years and 19 were females. Eight patients had episodic and 17 chronic migraine. β endorphin level was significantly lower in migraine (4.35 ± 2.29 ng/ml) compared to controls (6.68 ± 2.93 ng/ml). β endorphin level was lower in chronic compared to episodic migraine (3.74 ± 2.20 versus 5.65 ± 2.02 ng/ml). Following rTMS, the headache frequency, severity, functional disability and analgesic intake significantly reduced on the seventh day of rTMS and remained significant until the fourth week compared to the baseline. The clinical improvement was associated with increase in β endorphin level (4.35 ± 2.29 versus 6.58 ± 3.33 ng/ml).
    Conclusion: It can be concluded from this study that the basal plasma β endorphin level was low in migraine patients, especially in chronic migraine. The improvement in migraine after rTMS was associated with increase in β endorphin level.
    MeSH term(s) Adult ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Male ; Middle Aged ; Migraine Disorders/blood ; Migraine Disorders/therapy ; Transcranial Magnetic Stimulation ; Treatment Outcome ; Young Adult ; beta-Endorphin/blood
    Chemical Substances beta-Endorphin (60617-12-1)
    Language English
    Publishing date 2013-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 604567-4
    ISSN 1468-2982 ; 0333-1024
    ISSN (online) 1468-2982
    ISSN 0333-1024
    DOI 10.1177/0333102412473372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top